R&D Trends

Envigo expands R&D capabilities for in vitro assays

Friday, March 17, 2017

Envigo announces that it will develop and internally validate five to seven ion channel In vitro tests for measuring cardiac risk potential ahead of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of this year. These assays will form an integrated suite of tests that include the company’s existing hERG (Human Ether-à-go-go-Related Gene) assay.

[Read More]

BioSig Technologies, Mayo Clinic partner

Friday, March 17, 2017

BioSig Technologies, a medical device company developing the PURE EP System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, has signed a 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration with Mayo builds upon the work realized under the Advanced Clinical Research Program that was signed with Mayo Clinic in March 2016.

[Read More]

Allergan, Editas Medicine partner on CRISPR genome editing medicines for eye diseases

Wednesday, March 15, 2017

Allergan, a global pharmaceutical company, and Editas Medicine, a genome editing company, have announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical development.

[Read More]

Vedantra, Neon Therapeutics partner to develop cancer vaccines

Wednesday, March 15, 2017

Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has announced a joint collaboration to explore cancer vaccine research with Neon Therapeutics, an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. The two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantra’s cutting edge albumin-binding, lymph node targeting amphiphile technology with Neon’s innovative capabilities in neoantigen vaccine research.

[Read More]

Dementia Consortium funds dementia treatments team

Wednesday, March 15, 2017

The Dementia Consortium, a public-private partnership initiative bridging the gap between academic research and the pharmaceutical industry, is supporting a project led by Dr. David Brough at the University of Manchester to develop novel therapeutics for Alzheimer’s disease targeting the immune system. This is the fifth project supported by the Dementia Consortium, and has been awarded £191,757 by the initiative.

[Read More]

MRC Technology licenses antibody to Newsummit Biopharma for hepatitis C

Tuesday, March 14, 2017

MRC Technology, a medical research charity, has licensed an antibody to Newsummit Biopharma, a China-based drug development process solutions provider, for development of a novel therapeutic for treatment of Hepatitis C virus (HCV) infection. The antibody was humanized by MRC Technology scientists, and originated in the laboratory of Prof. Arvind Patel, of the MRC-University of Glasgow Centre for Virus Research (CVR).

[Read More]

ReadCoor joins the Wyss Institute’s IARPA MICrONS brain mapping consortium

Tuesday, March 14, 2017

ReadCoor has joined the multi-disciplinary consortium led by the Wyss Institute for Biologically Inspired Engineering at Harvard University to map the brain’s neural circuitry with resolution and precision. The consortium is made possible through a $21 million contract from the Intelligence Advanced Research Projects Activity (IARPA) under the MICrONS program to discover the brain’s learning rules and synaptic ‘circuit design,’ further enhancing neurally-derived machine learning algorithms.

[Read More]